Back HCV Treatment

HCV Treatment

AASLD 2014: Sofosbuvir/ Ledipasvir + Ribavirin Highly Effective for People with Decompensated Cirrhosis

An oral regimen of sofosbuvir/ledipasvir (Harvoni) plus ribavirin taken for 12 weeks cured most hepatitis C patients with decompensated cirrhosis, the most advanced stage of liver disease, according to a presentation at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting this week in Boston. Sustained response was associated with improved liver function in most patients.

alt

Read more:

AASLD 2014: Sofosbuvir/Ledipasvir and AbbVie 3D Cure Most People with HCV Genotype 4

Sofosbuvir/ledipasvir (Harvoni) without ribavirin and AbbVie's 3D regimen (paritaprevir/ombitasvir plus dasabuvir) both produced high sustained virological response rates for patients with hepatitis C virus (HCV) genotype 4, according to a pair of studies presented at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting this week in Boston.

alt

Read more:

AASLD 2014: Sustained Response to HCV Treatment Reduces Mortality, Liver Cancer, Liver Transplants

People who achieve sustained virological response (SVR) when treated with interferon-based therapy for hepatitis C have a lower risk of death, are less likely to develop liver cancer, and need fewer liver transplants than those who were treated but not cured, according to results from a meta-analysis of more than 34,000 patients presented at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting this week in Boston.

alt

Read more:

AASLD 2014: Daclatasvir TRIO Regimen Has Good Cure Rates With or Without Cirrhosis

A 12-week oral regimen of daclatasvir, asunaprevir, and beclabuvir, with or without ribavirin, cured 86% to 90% of genotype 1 hepatitis C patients with cirrhosis in the Phase 3 UNITY-2 trial, while the TRIO regimen without ribavirin demonstrated similar sustained response rates for non-cirrhotics in UNITY-1, according to 2 late-breaking reports presented at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting this week in Boston. Findings suggest that ribavirin is still useful for some harder-to-treat patients.

alt

Read more:

AASLD 2014: Sofosbuvir/Ledipasvir Cures Nearly All Genotype 1 HIV/HCV Coinfected Patients

All but 1 participant treated with a coformulation of sofosbuvir and ledipasvir (Harvoni) achieved sustained virological response at 12 weeks post-treatment in a study looking at traditionally hard-to-treat HIV/HCV coinfected patients, researchers reported at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting this week in Boston.

alt

Read more: